Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Roivant Sciences Ltd. (ROIV)  
$16.17 0.19 (1.19%) as of 4:30 Fri 10/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 692,010,000
Market Cap: 11.19(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $9.08 - $15.98
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    : 5.8
Insider 6 Months    : 5.8
Insider 3/6 Months : 12
Guru Rank Number :  341
Guru Rank Value     : 6
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Roivant Sciences develops drug candidates in subsidiary companies Co. calls Vants. Co.'s Vants and pipeline include Dermavant Sciences Ltd., which is developing tapinarof for the treatment of psoriasis and atopic dermatitis, with an earlier-stage development pipeline; Immunovant, Inc., which is developing IMVT-1401 for the treatment of Myasthenia Gravis, Warm Autoimmune Hemolytic Anemia and Thyroid Eye Disease; Aruvant Sciences Ltd., which is developing ARU-1801 as a one-time, potentially curative gene therapy for the treatment of sickle cell disease; and Proteovant Sciences, Inc, which is developing heterobifunctional protein degraders for oncology, neurology, and immunology AR Degrader.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 3,315 3,315 3,315 3,315
Total Buy Value $49,957 $49,957 $49,957 $49,957
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 3,686,749 7,776,211 11,342,561 17,395,797
Total Sell Value $50,304,986 $96,391,342 $136,909,971 $205,480,260
Total People Sold 2 2 4 8
Total Sell Transactions 8 19 35 51
End Date 2025-07-06 2025-04-04 2024-10-04 2023-10-05

   
Records found: 502
  Page 1 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Pulik Richard CFO   •       •      –    2025-09-28 4 D $15.17 $35,513 D/D (2,341) 389,508     -
   Venker Eric President & Immunovant CEO   •       •      –    2025-09-23 4 AS $14.83 $9,061,130 D/D (611,000) 1,504,959 10%     
   Venker Eric President & Immunovant CEO   •       •      –    2025-09-22 4 AS $14.99 $6,240,568 D/D (416,182) 2,115,959 8%     
   Venker Eric President & Immunovant CEO   •       •      –    2025-09-22 4 OE $3.85 $2,165,140 D/D 562,374 2,532,141     -
   Pulik Richard CFO   •       •      –    2025-09-20 4 D $15.04 $32,020 D/D (2,129) 391,849     -
   Venker Eric President & Immunovant CEO   •       •      –    2025-09-19 4 AS $14.95 $10,223,079 D/D (683,818) 1,969,767 8%     
   Venker Eric President & Immunovant CEO   •       •      –    2025-09-19 4 OE $3.85 $3,850,000 D/D 1,000,000 2,653,585     -
   Gline Matthew CEO   •       •      –    2025-09-18 4 B $15.07 $49,957 D/D 3,315 17,287,081 0.01 6%     
   Manchester Keith S   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 1,948,403     -
   Momtazee James C   •       •      –    2025-09-10 4 D $13.77 $45,193 D/D (3,282) 107,912     -
   Momtazee James C   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 111,194     -
   Oren Ilan   •       •      –    2025-09-10 4 D $13.77 $28,132 D/D (2,043) 117,162     -
   Oren Ilan   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 119,205     -
   Epperly Melissa B,   •       •      –    2025-09-10 4 D $13.77 $22,872 D/D (1,661) 55,848     -
   Epperly Melissa B,   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 57,509     -
   Gold Daniel Allen   •       •      –    2025-09-10 4 D $13.77 $72,568 D/D (5,270) 8,965,894     -
   Gold Daniel Allen   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 8,971,164     -
   Fitzgerald Meghan   •       •      –    2025-09-10 4 D $13.77 $12,902 D/D (937) 42,963     -
   Fitzgerald Meghan   •       •      –    2025-09-10 4 A $0.00 $0 D/D 14,524 43,900     -
   Ramaswamy Vivek 10% Owner   –       –       •   2025-09-05 4 S $12.96 $5,000,175 D/D (385,816) 35,508,359 -24%     
   Ramaswamy Vivek 10% Owner   –       –       •   2025-09-04 4 S $12.92 $2,518,534 D/D (194,933) 35,894,175 -27%     
   Ramaswamy Vivek 10% Owner   –       –       •   2025-09-03 4 S $12.50 $14,937,500 D/D (1,195,000) 36,089,108 -27%     
   Pulik Richard CFO   •       •      –    2025-08-28 4 D $11.94 $27,940 D/D (2,340) 393,978     -
   Pulik Richard CFO   •       •      –    2025-08-20 4 D $11.72 $14,474 D/D (1,235) 396,318     -
   Venker Eric President & Immunovant CEO   •       •      –    2025-08-20 4 AS $11.72 $1,172,000 D/D (100,000) 1,653,585 38%     

  502 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed